Last reviewed · How we verify
Perflutren Lipid Microsphere Injectable Suspension
At a glance
| Generic name | Perflutren Lipid Microsphere Injectable Suspension |
|---|---|
| Also known as | DEFINITY |
| Sponsor | University of Pennsylvania |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer (PHASE1)
- A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography (PHASE1, PHASE2)
- Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) (PHASE1)
- Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy (PHASE1)
- Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography (PHASE3)
- Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema (PHASE1)
- Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma (EARLY_PHASE1)
- Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: